HighTower Advisors’s Viking Therapeutics VKTX Stock Holding History

HighTower Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,000	Closed	-$10.2K	–	4077
2025 Q2	$10.2K	Buy	2,000 +1,000	+100%	+$26.3K	﹤0.01%	3645
2025 Q1	$1.54K	Sell	1,000 -2,600	-72%	-$82.2K	﹤0.01%	3636
2024 Q4	$12.3K	Buy	3,600 +3,100	+620%	+$177K	﹤0.01%	3575
2024 Q3	$1.66K	Sell	500 -300	-38%	-$17.6K	﹤0.01%	3645
2024 Q2	$6.24K	Buy	+800	New	+$52.4K	﹤0.01%	3470
2019 Q2	–	Sell	-1,000	Closed	-$2K	–	2519
2019 Q1	$2K	Buy	+1,000	New	+$8.37K	﹤0.01%	2258

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

HighTower Advisors's VKTX Position: Q2 2026 in Review

HighTower Advisors opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 6,096 shares worth $238K. The stake represents ﹤0.01% of the portfolio and ranks #3411 among its holdings. This is a return to the name: HighTower Advisors previously reported a position in VKTX as recently as Q4 2025.

HighTower Advisors first reported a position in VKTX in Q3 2018 and has held it in 17 quarters since. The position peaked at $507K in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

HighTower Advisors held 6,096 shares of Viking Therapeutics worth $238K as of Q2 2026.
Viking Therapeutics was a new HighTower Advisors position in Q2 2026.
Viking Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3411 holding.
HighTower Advisors first reported a position in Viking Therapeutics in Q3 2018 and has held it in 17 quarters since.
HighTower Advisors's Viking Therapeutics position peaked at $507K in Q3 2024.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.